Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The stem cell–derived transplants were stable for 24 months and led to wide-ranging behavioral improvements in the monkeys.  

Two patients became legally blind after receiving treatments at the facilities.

Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 

Four products have already qualified for the regenerative medicine advanced therapy (RMAT) designation that provides extra interactions with the agency, and sooner.

The UK Stem Cell Bank offers several lines derived from human embryonic tissue.

Researchers use an inducible gene to limit tumor growth from human iPSCs transplanted into mice.

Injections of progenitor cells into damaged rat hearts may improve function, but not because the implants themselves are creating new muscle.

California’s stem cell agency unveiled a 5-year plan that includes starting 50 new clinical trials.